HR23b expression is a potential predictive biomarker for HDAC inhibitor treatment in mesenchymal tumours and is associated with response to vorinostat.
about
HDAC and Proteasome Inhibitors Synergize to Activate Pro-Apoptotic Factors in Synovial SarcomaVorinostat in combination with capecitabine plus cisplatin as a first-line chemotherapy for patients with metastatic or unresectable gastric cancer: phase II study and biomarker analysis.Entinostat: a promising treatment option for patients with advanced breast cancer.YY1 promotes HDAC1 expression and decreases sensitivity of hepatocellular carcinoma cells to HDAC inhibitorHistone deacetylase inhibitors vorinostat and panobinostat induce G1 cell cycle arrest and apoptosis in multidrug resistant sarcoma cell lines.
P2860
HR23b expression is a potential predictive biomarker for HDAC inhibitor treatment in mesenchymal tumours and is associated with response to vorinostat.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 05 February 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
HR23b expression is a potentia ...... d with response to vorinostat.
@en
HR23b expression is a potentia ...... d with response to vorinostat.
@nl
type
label
HR23b expression is a potentia ...... d with response to vorinostat.
@en
HR23b expression is a potentia ...... d with response to vorinostat.
@nl
prefLabel
HR23b expression is a potentia ...... d with response to vorinostat.
@en
HR23b expression is a potentia ...... d with response to vorinostat.
@nl
P2093
P2860
P50
P356
P1476
HR23b expression is a potentia ...... d with response to vorinostat.
@en
P2093
Eva Wardelmann
Florence Pedeutour
Hiroshi Sonobe
Jun Nishio
Nancy Ratner
Olle Larsson
Reinhard Buettner
Sebastian Bauer
Takahiro Taguchi
P2860
P356
10.1002/CJP2.35
P577
2016-02-05T00:00:00Z